Healthcare Nanotechnology (Nanomedicine) Market Size, Growth, Trends | Report 2023-2032
The global healthcare nanotechnology (nanomedicine) market was surpassed at USD 195.58 billion in 2022 and is expected to hit around USD 674.54 billion by 2032, growing at a CAGR of 13.18% from 2023 to 2032.
-Market-Size.jpg)
Key Pointers
Report Scope of the Healthcare Nanotechnology (Nanomedicine) Market
| Report Coverage | Details |
| Market Size in 2022 | USD 195.58 billion |
| Revenue Forecast by 2032 | USD 674.54 billion |
| Growth rate from 2023 to 2032 | CAGR of 13.18% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Covered | Sanofi SA, Abbott, Pfizer Inc., CombiMatrix Corporation, GE Healthcare, Celgene Corporation, Johnson & Johnson Services, Inc. |
Nanotechnology is one of the foremost promising technologies in the 21st century. Nanotechnology may be a term used when technological developments occur at a 0.1 to 100 nm scale. Nanomedicine is usually a branch of nanotechnology as it involves medicine development at a molecular scale for diagnosis, prevention, treatment of diseases, and even regeneration of tissues and organs. Nanotechnology is one of the foremost promising technologies in the 21st century. Nanotechnology may be a term used when technological developments occur at a 0.1 to 100 nm scale. Nanomedicine is usually a branch of nanotechnology as it involves medicine development at a molecular scale for diagnosis, prevention, treatment of diseases, and even regeneration of tissues and organs.
Preserving and improving human health helps in doing so. For various life-threatening diseases like orthopedic problems, diseases related to blood, lungs, cancer, Parkinson’s, Alzheimer’s, diabetes, neurological, and cardiovascular system Nanomedicine offers a strong solution. These are multifunctional drugs with programmable properties which help in finding the applications such as monitoring, construction, repair, and control of biological systems at the molecular level using nanodevices and nanoparticles. Development of a replacement nanomedicine takes several years which is supported by various technologies like dendrimers, micelles, nanocrystals, fullerenes, virosome nanoparticles, nanopores, liposomes, nanorods, nanoemulsions, quantum dots, and nanorobots.
Nanomedicine may be a promising mode of cancer treatment. This growing field of medical research is often wont to discover a better-personalized treatment for a good range of diseases, including cancer. As nanomedicine promises to develop innovative drugs which have greater efficacy and lesser side effects than standard therapies because of its benefits as it has the properties of matter at the nanoscale. The necessity for technological advancements to reinforce disease diagnosis, treatment, and prevention is thus found to be the main driver for the Healthcare Nanotechnology (Nanomedicine) Market. Within the case of cancers, nanomedicine offers promising changes from the present methods of diagnosing and treating cancer.
Market Overview
Nanomedicines have the potential which can fully change or revolutionalize the current scenario of detection of disease, diagnosis, and treatment methods. With the emergence of innovative technologies such as drug delivery, and also there are several benefits of nanomedicine that will significantly boost the Global Healthcare Nanotechnology (Nanomedicine) Market. Rising government funding and support will lead to an increase in demand for the market as well as its safe and cost-effective therapies will support the market growth.
The increasing out-licensing of nano drugs and the growth of healthcare facilities in emerging economies help in creating an ample amount of opportunities for market growth. Technological advancements including relevant applications in early disease diagnosis, preventive intervention, and prophylaxis of chronic also as acute disorders are expected to bolster growth in this market. Nanotechnology involves The miniaturization of larger structures and chemicals at a nanometric scale involves Nanotechnology rapidly revolutionized drug administration, thus influencing the adoption of the technology.
Healthcare Nanotechnology (Nanomedicine) Market Segmentations:
| By Modality | By Indication | By Application |
|
Treatment Diagnostics |
Clinical oncology Infectious diseases Clinical cardiology Orthopedics Neurology Urology Ophthalmology Immunology Others |
Drug delivery Regenerative medicine Implants Diagnostic Imaging Vaccines Others |
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Modality Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Healthcare Nanotechnology (Nanomedicine) Market
5.1. COVID-19 Landscape: Healthcare Nanotechnology (Nanomedicine) Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Healthcare Nanotechnology (Nanomedicine) Market, By Modality
8.1. Healthcare Nanotechnology (Nanomedicine) Market, by Modality, 2023-2032
8.1.1 Treatment
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Diagnostics
8.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Healthcare Nanotechnology (Nanomedicine) Market, By Indication
9.1. Healthcare Nanotechnology (Nanomedicine) Market, by Indication, 2023-2032
9.1.1. Clinical oncology
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Infectious diseases
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Clinical cardiology
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Orthopedics
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Neurology
9.1.5.1. Market Revenue and Forecast (2020-2032)
9.1.6. Urology
9.1.6.1. Market Revenue and Forecast (2020-2032)
9.1.7. Ophthalmology
9.1.7.1. Market Revenue and Forecast (2020-2032)
9.1.8. Immunology
9.1.8.1. Market Revenue and Forecast (2020-2032)
9.1.9. Others
9.1.9.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Healthcare Nanotechnology (Nanomedicine) Market, By Application
10.1. Healthcare Nanotechnology (Nanomedicine) Market, by Application, 2023-2032
10.1.1. Drug delivery
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Regenerative medicine
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Implants
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Diagnostic
10.1.4.1. Market Revenue and Forecast (2020-2032)
10.1.5. Imaging
10.1.5.1. Market Revenue and Forecast (2020-2032)
10.1.6. Vaccines
10.1.6.1. Market Revenue and Forecast (2020-2032)
10.1.7. Others
10.1.7.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Healthcare Nanotechnology (Nanomedicine) Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Modality (2020-2032)
11.1.2. Market Revenue and Forecast, by Indication (2020-2032)
11.1.3. Market Revenue and Forecast, by Application (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Modality (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Indication (2020-2032)
11.1.4.3. Market Revenue and Forecast, by Application (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Modality (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Indication (2020-2032)
11.1.5.3. Market Revenue and Forecast, by Application (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Modality (2020-2032)
11.2.2. Market Revenue and Forecast, by Indication (2020-2032)
11.2.3. Market Revenue and Forecast, by Application (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Modality (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Indication (2020-2032)
11.2.4.3. Market Revenue and Forecast, by Application (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Modality (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Indication (2020-2032)
11.2.5.3. Market Revenue and Forecast, by Application (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Modality (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Indication (2020-2032)
11.2.6.3. Market Revenue and Forecast, by Application (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Modality (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Indication (2020-2032)
11.2.7.3. Market Revenue and Forecast, by Application (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Modality (2020-2032)
11.3.2. Market Revenue and Forecast, by Indication (2020-2032)
11.3.3. Market Revenue and Forecast, by Application (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Modality (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Indication (2020-2032)
11.3.4.3. Market Revenue and Forecast, by Application (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Modality (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Indication (2020-2032)
11.3.5.3. Market Revenue and Forecast, by Application (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Modality (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Indication (2020-2032)
11.3.6.3. Market Revenue and Forecast, by Application (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Modality (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Indication (2020-2032)
11.3.7.3. Market Revenue and Forecast, by Application (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Modality (2020-2032)
11.4.2. Market Revenue and Forecast, by Indication (2020-2032)
11.4.3. Market Revenue and Forecast, by Application (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Modality (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Indication (2020-2032)
11.4.4.3. Market Revenue and Forecast, by Application (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Modality (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Indication (2020-2032)
11.4.5.3. Market Revenue and Forecast, by Application (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Modality (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Indication (2020-2032)
11.4.6.3. Market Revenue and Forecast, by Application (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Modality (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Indication (2020-2032)
11.4.7.3. Market Revenue and Forecast, by Application (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Modality (2020-2032)
11.5.2. Market Revenue and Forecast, by Indication (2020-2032)
11.5.3. Market Revenue and Forecast, by Application (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Modality (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Indication (2020-2032)
11.5.4.3. Market Revenue and Forecast, by Application (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Modality (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Indication (2020-2032)
11.5.5.3. Market Revenue and Forecast, by Application (2020-2032)
Chapter 12. Company Profiles
12.1. Sanofi SA
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Abbott
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Pfizer Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. CombiMatrix Corporation
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. GE Healthcare
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Celgene Corporation
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Johnson & Johnson Services, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers